Grifols voluntarily discloses transfers of value

The company adopted the EFPIA Code of Conduct in 2015

• In line with its longstanding commitment to transparency, Grifols has disclosed, for the second consecutive year, all of its payments and other transfers of value to health professionals and health sector organizations in 33 European countries, including Spain.
• Grifols' transfers of value in Spain in 2016 totaled Euros 5.25 million, compared to Euros 9.55 million in 2015, representing a 45% year-on-year decrease.
• The transfers of value derived from R&D activities in Spain exceeded Euros 4 million in 2016. This represents nearly half of all transfers of value related to R&D initiatives realized by the Group in Europe.
• In 2016, Grifols made transfers of value in Spain to 426 healthcare professionals that totaled Euros 459,839 (-18% compared to 2015) and to 62 healthcare organizations that totaled Euros 762,418 (-3.5% compared to 2015).
• The Code of Conduct on Industry Interactions with Healthcare Professionals and Healthcare Organizations of the European Federation of Pharmaceutical Industries and Associations (EFPIA) applies specifically to medicines. Nonetheless, Grifols opted to expand its scope of application to include transfers unrelated to medications, as well as to the company's three divisions: Bioscience, Diagnostic and Hospital.
• Grifols applies this transparency policy in the United States as required by the regulatory body (Centers for Medicaid and Medicare Services, or CMS) and, in addition to Europe, also plans to implement it in countries such as Australia and Japan.
• All the information is available on the Grifols' corporate website: www.grifols.com